These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22898800)

  • 21. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
    Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J
    J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System.
    Lerman JB; Patel CB; Casalinova S; Nicoara A; Holley CL; Leacche M; Silvestry S; Zuckermann A; D'Alessandro DA; Milano CA; Schroder JN; DeVore AD
    Circ Heart Fail; 2024 May; 17(5):e010904. PubMed ID: 38602105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation.
    Nativi JN; Drakos SG; Kucheryavaya AY; Edwards LB; Selzman CH; Taylor DO; Hertz MI; Kfoury AG; Stehlik J
    J Heart Lung Transplant; 2011 Aug; 30(8):854-61. PubMed ID: 21571550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality in status 2 patients listed for heart transplantation in the United States: Will understanding cause of death help justify implantation of left ventricular assist devices into less sick patients?
    Morris AA; Chen C; Laskar SR; Smith AL; Vega JD
    Int J Cardiol; 2019 Feb; 276():185-190. PubMed ID: 30482444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe right ventricular dysfunction is an independent predictor of pre- and post-transplant mortality among candidates for heart transplantation.
    Ravis E; Theron A; Mancini J; Jaussaud N; Morera P; Chalvignac V; Guidon C; Grisoli D; Gariboldi V; Riberi A; Habib G; Mouly-Bandini A; Collart F
    Arch Cardiovasc Dis; 2017 Mar; 110(3):139-148. PubMed ID: 28117247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporary left ventricular assist devices as a bridge to heart transplantation.
    Seese L; Hickey G; Keebler ME; Mathier MA; Sultan I; Gleason TG; Wang Y; Kilic A
    J Card Surg; 2020 Apr; 35(4):810-817. PubMed ID: 32092194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do Patients Supported With Continuous-flow Left Ventricular Assist Device Have a Sufficient Risk of Death to Justify a Priority Allocation? A Propensity Score Matched Analysis of Patients Listed in UNOS Status 2.
    Mastrobuoni S; Dell'Aquila AM; Van Caenegem O; Poncelet A; Jacquet LM; Garcia J
    Transplantation; 2018 Jun; 102(6):e288-e294. PubMed ID: 29346259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation.
    Steffen RJ; Blackstone EH; Smedira NG; Soltesz EG; Hoercher KJ; Thuita L; Starling RC; Mountis M; Moazami N
    Ann Thorac Surg; 2017 Nov; 104(5):1569-1576. PubMed ID: 28651783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does successful bridging with ventricular assist device affect cardiac transplantation outcome?
    Urban M; Pirk J; Dorazilova Z; Netuka I
    Interact Cardiovasc Thorac Surg; 2011 Oct; 13(4):405-9. PubMed ID: 21788304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?
    Kirklin JK; Naftel DC; Pagani FD; Kormos RL; Stevenson L; Miller M; Young JB
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):584-603; discussion 597-8. PubMed ID: 22795459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of ventricular assist device complications on posttransplant survival: an analysis of the United network of organ sharing database.
    Healy AH; Baird BC; Drakos SG; Stehlik J; Selzman CH
    Ann Thorac Surg; 2013 Mar; 95(3):870-5. PubMed ID: 23218024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality.
    Truby LK; Farr MA; Garan AR; Givens R; Restaino SW; Latif F; Takayama H; Naka Y; Takeda K; Topkara VK
    Circulation; 2019 Aug; 140(6):459-469. PubMed ID: 31203669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transplant registrants with implanted left ventricular assist devices have insufficient risk to justify elective organ procurement and transplantation network status 1A time.
    Dardas T; Mokadam NA; Pagani F; Aaronson K; Levy WC
    J Am Coll Cardiol; 2012 Jul; 60(1):36-43. PubMed ID: 22541833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of cardiac transplantation in patients requiring prolonged continuous-flow left ventricular assist device support.
    Takeda K; Takayama H; Kalesan B; Uriel N; Colombo PC; Jorde UP; Yuzefpolskaya M; Mancini DM; Naka Y
    J Heart Lung Transplant; 2015 Jan; 34(1):89-99. PubMed ID: 25444372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices--An analysis of the International Society for Heart and Lung Transplantation Transplant Registry.
    Healy AH; Stehlik J; Edwards LB; McKellar SH; Drakos SG; Selzman CH
    J Heart Lung Transplant; 2016 Jan; 35(1):34-39. PubMed ID: 26296960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Left ventricular assist devices as bridge to heart transplantation: The Niguarda Experience.
    Vitali E; Lanfranconi M; Bruschi G; Russo C; Colombo T; Ribera E
    J Card Surg; 2003; 18(2):107-13. PubMed ID: 12757336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous flow left ventricular assist device technology has influenced wait times and affected donor allocation in cardiac transplantation.
    Taghavi S; Jayarajan SN; Komaroff E; Mangi AA
    J Thorac Cardiovasc Surg; 2014 Jun; 147(6):1966-71, 1971.e1. PubMed ID: 24613158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Therapeutic Modification on Outcomes in Heart Transplantation Over the Past Two Decades　- A Single-Center Experience in Japan.
    Yanase M; Iwasaki K; Watanabe T; Seguchi O; Nakajima S; Kuroda K; Mochizuki H; Matsuda S; Takenaka H; Ikura M; Tadokoro N; Fukushima S; Fujita T; Ishibashi-Ueda H; Nakatani T; Kitamura S; Kobayashi J; Tsujita K; Ogawa H; Fukushima N
    Circ J; 2020 May; 84(6):965-974. PubMed ID: 32350231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.